An open biopsy, non-healing wound, ulcer or significant traumatic injury within 28 days prior to starting treatment (percutaneous, endobronchial, and endoscopic biopsies are allowed)
Major surgery, open biopsy or significant traumatic injury within 4 weeks prior to study entry
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Had major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to day 1 of treatment on study
A major surgical procedure, open biopsy, or significant traumatic injury within 3 months prior to cycle 1 day 1 (percutaneous/endobronchial/endoscopic biopsies are allowed)
Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to “on-study” status
FOR ALL PHASES (Ib AND II): Major surgical procedure or significant traumatic injury (as judged by the investigator) within 28 days before start of study medication, open biopsy within 7 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days of day 1 of therapy.
Major surgery, open biopsy or significant traumatic injury within 28 days before the start of study treatment
A major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib (percutaneous/endobronchial biopsies are allowed)
Major surgical procedure, open biopsy or significant traumatic injury =< 28 days prior to registration
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days of day 1 of therapy
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug
Had major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of treatment on study
Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to being registered for protocol therapy
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration (biliary stenting or percutaneous biliary drainage are not included)
Major surgical procedure, open biopsy, or significant traumatic injury less than 3 weeks or those who receive minor surgical procedures (eg core biopsy or fine needle aspiration) within 1 week from first dose of first study drug administration
Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization on this study
Craniotomy or any other major surgery, open biopsy, or significant traumatic injury within 4 weeks of enrollment
Major surgery (including ostomy reversal), open biopsy or significant trauma injury, within 28 days prior to randomization.
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication.
Had major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of treatment on study
Subject has undergone a major surgical procedure, open biopsy, radiofrequency ablation or has experienced a significant injury within 28 days prior to enrollment
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting nivolumab and bevacizumab
Major surgical procedure, open biopsy, or significant traumatic injury =< 56 days prior to randomization
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury =< 28 days prior to randomization
Participants may not have a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib
Major surgical procedure, open biopsy, or significant traumatic injury =< 4 weeks prior to registration/randomization; (port-a-cath placement does not count as a major surgical procedure and patients can be enrolled at any time after placement)
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgery, open biopsy or significant traumatic injury within 2 weeks of first dose of study drug
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgical procedure, laparoscopic procedure, open biopsy or significant traumatic injury within 28 days prior to enrollment
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration (with the exception of craniotomy)
For patients who have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment, or anticipate the need for such while on active treatment, may participate and receive bevacizumab at the start of the second or third cycle as they would under standard care; placement of vascular access device is not considered major surgery, but the incision must have healed before initiation of treatment
Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open biopsy, or significant traumatic injury =< 28 days or core biopsy =< 7 days prior to randomization
Serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to being registered for protocol therapy
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of day 1 of treatment with FOLFIRI
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment.
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 therapy
No major surgery, open biopsy or significant traumatic injury within 4 weeks of start of first dose
Major surgery, open biopsy or significant traumatic injury within 4 weeks of starting therapy
Major surgical procedure, open biopsy, or significant traumatic injury within 3 weeks before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 3 weeks before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 of therapy
Major surgical procedure, open biopsy, or significant traumatic injury less than 4 weeks or those who receive minor surgical procedures (e.g. core biopsy or fine needle aspiration) within 1 week from first dose of first study drug administration
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1 or abdominal surgery, abdominal interventions or significant abdominal traumatic injury within 60 days prior to Day 1 of Cycle 1
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before registration
Craniotomy or any other major surgery, open biopsy, or significant traumatic injury within 4 weeks of enrollment
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of treatment (or anticipated need during study)
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug
Any serious non-healing wound, ulcer, bone fracture, major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to starting treatment with bevacizumab; if surgically cleared for chemotherapy on trial, bevacizumab may be delayed as clinically indicated up to 8 weeks after such procedures
Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication; minor procedures such as diagnostic laparoscopy, percutaneous biopsy and paracentesis within 14 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 of Cycle 1
Craniotomy or any other major surgery, open biopsy, or significant traumatic injury within 4 weeks of randomization